Susan was diagnosed with stage 1a melanoma. Her doctor ordered Castle Biosciences’ DecisionDx-Melanoma test, so she knew her cancer would be aggressive, and a higher risk for metastasis.
She was put on higher intensity surveillance, and when her cancer spread, it was caught early. Six months later, Susan’s scans are clear. BrightEdge invests in companies like Castle Biosciences, because early detection is a key step toward a world without cancer.